Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed SGLT2 inhibitor for type-2 diabetes ...
The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...
DelveInsight's "ROZLYTREK Market Size, Forecast, and Market Insight Report" highlights the details around ROZLYTREK, an ...
DelveInsight’s, “Nonalcoholic Steatohepatitis Pipeline Insight” report provides comprehensive insights about 80+ companies ...
Roche (RHHBY) is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker ...
The two companies will work together on Zealand’s amylin analogue petrelintide as a monotherapy and in combination therapies.
Ever-Growing USA on MSN1d
Retratutide: Eli Lilly’s Groundbreaking Drug Poised to Transform Obesity and Diabetes TreatmentIn the ever-evolving landscape of healthcare, groundbreaking innovations are not merely celebrated for their scientific ...
Looking for ways to supercharge a Stocks and Shares ISA? These hot takes could help investors to build a seven-figure ...
DelveInsight's 'BREYANZI Market Size, Forecast, and Market Insight Report' highlights the details around BREYANZI, a CD19-directed CAR ...
Viking Therapeutics has inked a $150m multi-year manufacturing deal with CordenPharma to secure the future supply of its ...
Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback